Eternygen Company
Eternygen is a Berlin based start up founded in June 2012 focusing on research and development of innovative drugs using a network of renowned scientists and contract research organizations. The main focus of Eternygen’s development and core competences of its founders are research and development of new drugs for dietary-related metabolic diseases with dramatically increasing prevalences in the last decades. Eternygen’s research addresses the sodium coupled citrate transporter NaCT which is a key regulator of lipid metabolism involved in the pathogenesis of fatty liver, diabetes and obesity. Company’s emphasis is the development of a safe and effective drug for treatment of these widespread diseases via targeted adjustment of underlying metabolic failure.
Industry:
Geroscience
Headquarters:
Berlin, Berlin, Germany
Zip:
1-10
Founded Date:
2012-06-01
Employees Number:
1-10
Acquisitions Number:
3
Investors Number:
8468001
Total Funding:
$1M to $10M
Estimated Revenue:
$1M to $10M
Last Funding Date:
Series A
Last Funding Type:
Series A
Register and Claim Ownership